Phase II study of interferon gamma in malignant carcinoid tumors (E9292): A trial of the eastern cooperative oncology group

Keith Stuart*, Donna E. Levy, Tom Anderson, Constantine A. Axiotis, Janice P. Dutcher, Andrew Eisenberg, John K. Erban, Al Bowen Benson

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


Purpose: To determine the safety and efficacy of treatment with gamma interferon (IFNγ) in patients with metastatic carcinoid tumor. Patients and methods: 51 patients were enrolled on this Phase II Eastern Cooperative Oncology Group (ECOG) study. Seventy five percent of them had hormonally active tumors. Treatment consisted of IFNγ subcutaneously at a daily dose of 0.1 mg/m2. Patents were evaluated for toxicity weekly for the first month and monthly thereafter; response was determined radiologically every 8 weeks. Results: Patients received treatment with IFNγ for a median of 17. 9 weeks (range 2-175). Toxicity was generally mild and expected: 61% experienced noninfected fever and 21% developed granulocytopenia. Three patients (6%) had a partial response; there were no complete responses. Median time to progression was 5.5 months (95% confidence interval 3.9-11.1). The 1-year progression free rate was 28% (13.4-43.4%). Median survival was 42 months, with a 1-year survival rate of 67% (53.3-80%). Discussion: This Phase II study demonstrated that therapy with IFNγ in patients with metastatic carcinoid tumor was well-tolerated, but did not produce significant antitumor effects. The overall results were somewhat comparable to those previously seen with alpha interferons as well as cytotoxic drugs.

Original languageEnglish (US)
Pages (from-to)75-81
Number of pages7
JournalInvestigational New Drugs
Issue number1
StatePublished - Jan 2004


  • Carcinoid
  • Interferon

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Phase II study of interferon gamma in malignant carcinoid tumors (E9292): A trial of the eastern cooperative oncology group'. Together they form a unique fingerprint.

Cite this